Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
- 1 July 2011
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 68 (7), 899-904
- https://doi.org/10.1001/archneurol.2011.139
Abstract
Antipsychotic (AP) use is common in Parkinson disease (PD), but APs can worsen parkinsonism, evidence for efficacy is limited, and use in patients with dementia increases mortality. To examine the frequency and characteristics, including changes over time, of AP use in a large cohort of patients with PD. Using Veterans Affairs data from fiscal year (FY) 2008, rates and predictors of AP prescribing were determined for patients with PD and psychosis stratified by dementia status (N = 2597) and a comparison group of patients with dementia and psychosis without PD (N = 6907). Fiscal year 2008 and FY2002 data were compared to examine changes in AP prescribing over time. Department of Veterans Affairs outpatient facilities. Outpatients with PD and psychosis and outpatients without PD with dementia and psychosis, all receiving care at Veterans Affairs facilities in FY2002 and FY2008. Antipsychotic prescribing, including overall, class, and specific medications. In FY2008, 50% of patients with PD having a diagnosis of psychosis were prescribed an AP. Among treated patients, the atypical AP quetiapine was most frequently prescribed (66%), but approximately 30% received high-potency APs. Clozapine was rarely prescribed (<2%). In multivariate models, diagnoses of PD and dementia were associated with AP use. Comparing FY2008 with FY2002, AP use in PD was unchanged, with decreases in risperidone and olanzapine use offset by an increase in quetiapine prescribing and the introduction of aripiprazole. Half of the patients with PD and psychosis receive APs, not uncommonly high-potency agents associated with worsening parkinsonism, and frequency of use has been unchanged since the "black box" warning for AP use in patients with dementia was issued. Recent trends are a shift to quetiapine use and the common use of aripiprazole. As psychosis and dementia are frequently comorbid in PD, safety risks associated with AP use in this population need to be assessed.This publication has 37 references indexed in Scilit:
- Impact of standard of care for psychosis in Parkinson diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Potential Causes of Higher Mortality in Elderly Users of Conventional and Atypical Antipsychotic MedicationsJournal of the American Geriatrics Society, 2008
- Antipsychotics for people with dementiaBMJ, 2008
- Presentation and Management of Psychosis in Parkinson’s Disease and Dementia With Lewy BodiesAmerican Journal of Psychiatry, 2007
- Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysisEuropean Neuropsychopharmacology, 2007
- Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilizationInternational Journal of Geriatric Psychiatry, 2006
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseThe New England Journal of Medicine, 2006
- Psychosis in Parkinson’s diseaseHeart, 2005
- Psychosis in Parkinson’s DiseaseJournal of Geriatric Psychiatry and Neurology, 2004
- Treatment of Psychosis in Parkinson???s DiseaseDrug Safety, 2003